Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Respiratory entities : Pfizer, inc. save search
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
Published: 2023-08-21 (Crawled : 00:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.14%
H: 1.3%
C: 0.82%
fda active vaccine respiratory virus
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
Published: 2022-12-19 (Crawled : 12:20) - globenewswire.com
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: 1.48%
H: 34.31%
C: 21.9%
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.23%
H: 0.56%
C: -0.31%
candidate respiratory virus
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
Published: 2022-12-07 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.08%
H: 2.81%
C: 0.98%
fda candidate disease vaccine application respiratory license virus review
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 3.11%
H: 0.88%
C: 0.02%
candidate global vaccine respiratory virus trial positive
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-08-25 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: 0.8%
candidate vaccine respiratory virus trial positive
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Published: 2022-04-07 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: -0.7%
H: 5.54%
C: 5.07%
respiratory virus
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
Published: 2022-03-24 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: -1.07%
H: 0.58%
C: 0.1%
fda respiratory granted therapy vaccine designation order
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women
Published: 2022-03-02 (Crawled : 12:30) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: 0.0%
fda respiratory granted active therapy women vaccine breakthrough therapy grant designation
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Published: 2021-09-02 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.96%
H: 0.84%
C: 0.77%
respiratory vaccine phase 3 trial
Respiratory Syncytial Virus (RSV) Market to Reach $4.2 Billion by 2027: CAGR 14.9%: Astute Analytica
Published: 2021-08-12 (Crawled : 10:00) - prnewswire.com
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.41%
H: 1.94%
C: 1.59%
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: 0.01%
H: 0.85%
C: 0.79%
respiratory
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
LICN | $0.7885 40.8% 11M
|
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.